Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Recruiting 7Completed 4Terminated 3Not yet recruiting 3Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Breast Neoplasms 6384Neoplasms 5356Prostatic Neoplasms 2964Carcinoma, Non-Small-Cell Lung 2704Colorectal Neoplasms 2674Lung Neoplasms 2262Multiple Myeloma 1656Lymphoma 1598Neoplasm Metastasis 1550Leukemia, Myeloid, Acute 1537Melanoma 1484Pancreatic Neoplasms 1470Ovarian Neoplasms 1420Leukemia 1387Head and Neck Neoplasms 1283Precursor Cell Lymphoblastic Leukemia-Lymphoma 1279Lymphoma, Non-Hodgkin 1226Colonic Neoplasms 1157Carcinoma, Hepatocellular 1141Stomach Neoplasms 1126Leukemia, Lymphocytic, Chronic, B-Cell 1089Brain Neoplasms 1048Rectal Neoplasms 979Lymphoma, Follicular 978Recurrence 971Uterine Cervical Neoplasms 923Glioblastoma 916Carcinoma, Renal Cell 881Lymphoma, Large B-Cell, Diffuse 851Hodgkin Disease 775

Interventions

vanucizumab 1selicrelumab 1pembrolizumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Advanced/Metastatic Solid Tumors × Clear all
NCT04501276 2026-01-08

A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients

Adagene Inc

Phase 1 Completed
72 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT04645069 2024-08-14

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

Adagene Inc

Phase 1/2 Completed
58 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT05277402 2024-02-26

ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Adagene Inc

Phase 1 Completed
6 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT02665416 2020-04-07

Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
94 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡